All Releases
 |
ARYx Therapeutics Inc. Updates Progress with Tecarfarin EmbraceAC Study
Jun 16, 2009
|
14.0 KB |
|
| |
FREMONT, Calif., Jun 16, 2009 (BUSINESS WIRE) -- ARYx Therapeutics Inc. (NASDAQ:ARYX), a biopharmaceutical company,
announced today that the database for the EmbraceAC study has been
locked and the study remains on schedule, with the efficacy and safety
results to be available during the week of July 6, 2009. The study was
...
|
|
ARYx to Present at the Jefferies 3rd Annual Healthcare Conference
Jun 10, 2009
|
9.5 KB |
|
| |
FREMONT, Calif., Jun 10, 2009 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced that it will
present at the Jefferies & Company 3rd Annual Healthcare Conference on
Wednesday, June 17, 2009 at 2:45 p.m. Eastern Time. A live webcast of
the presentation may be accessed at the ARYx website http://www.aryx....
|
|
ARYx Reports First Quarter 2009 Results and Earnings
May 14, 2009
|
19.0 KB |
|
| |
FREMONT, Calif., May 14, 2009 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (NASDAQ:ARYX) today reported results of
operations and provided an update on its products for the first quarter
ended March 31, 2009.
"During the first quarter, we remained on track with all of our lead
programs in order to meet our existing clinical a...
|
|
ARYx Therapeutics Schedules First Quarter 2009 Results and Earnings Call
May 7, 2009
|
9.7 KB |
|
| |
FREMONT, Calif., May 07, 2009 (BUSINESS WIRE) -- ARYx Therapeutics Inc (NASDAQ:ARYX), a biopharmaceutical company,
announced today that a conference call to discuss first quarter 2009
results will be held on Thursday, May 14, 2009 at 8:00 a.m. Pacific Time.
The dial-in information for the call is as follows:
Dial In: 877-741-4241
...
|
|
ARYx Reports Fourth Quarter and Full Year 2008 Results of Operations
Mar 26, 2009
|
21.1 KB |
|
| |
FREMONT, Calif., Mar 26, 2009 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (NASDAQ:ARYX) today reported results of
operations and provided an update on its products for the fourth quarter
and year ended December 31, 2008.
"2008 was an eventful and productive year for ARYx, as we have now
generated proof of concept for each of...
|
|
ARYx Therapeutics Schedules Fourth Quarter and Year End 2008 Results and Earnings Call
Mar 19, 2009
|
9.7 KB |
|
| |
FREMONT, Calif., Mar 19, 2009 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (NASDAQ:ARYX), a biopharmaceutical company,
announced today that a conference call to discuss fourth quarter and
year end 2008 results will be held on Thursday, March 26, 2009 at 8:00
a.m. Pacific Time.
The dial-in information for the call is as follow...
|
|
ARYx to Present at the Cowen and Company 29th Annual Healthcare Conference
Mar 13, 2009
|
9.5 KB |
|
| |
FREMONT, Calif., Mar 13, 2009 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced that it will
present at the Cowen and Company 29th Annual Healthcare
Conference Monday, March 16 at 4:40 p.m. Eastern Time. A live webcast of
the presentation may be accessed at the ARYx website http://www.aryx.com.
...
|
|
ARYx Therapeutics, Inc. Provides Additional Data on Atrial Fibrillation Clinical Trial on ATI-2042
Jan 12, 2009
|
17.5 KB |
|
| |
FREMONT, Calif., Jan 12, 2009 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (NASDAQ:ARYX), a biopharmaceutical company,
today announced further results from a Phase 2b clinical trial testing
the safety and efficacy of its oral anti-arrhythmic therapy, ATI-2042,
in patients with atrial fibrillation. This follows the December 18,...
|
|
ARYx Therapeutics, Inc. Announces Successful Outcome of Atrial Fibrillation Clinical Trial on ATI-2042
Dec 18, 2008
|
18.7 KB |
|
| |
FREMONT, Calif., Dec 18, 2008 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (NASDAQ:ARYX), a biopharmaceutical company,
today announced successful top-line efficacy results from a Phase 2b
clinical trial testing the safety and efficacy of its oral
anti-arrhythmic therapy, ATI-2042, in patients with atrial fibrillation.
...
|
|
ARYx to Present at the Piper Jaffray 20th Annual Healthcare Conference
Nov 25, 2008
|
9.5 KB |
|
| |
FREMONT, Calif., Nov 25, 2008 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced that it will
present at the Piper Jaffray Healthcare Conference in New York, NY. A
live webcast of the presentation scheduled for Tuesday, December 2 at
10:30 a.m. Eastern Time may be accessed at the ARYx website http://www...
|
|
ARYx Therapeutics Presents Clinical Data for ATI-5923 at American Heart Association Scientific Sessions 2008
Nov 14, 2008
|
15.3 KB |
|
| |
NEW ORLEANS, Nov. 14 /BusinessWire/ -- ARYx Therapeutics (NASDAQ; ARYX) announced today that clinical data for ATI-5923, a novel vitamin K epoxide reductase (VKOR) inhibitor in Phase 2/3 development for the treatment of patients at risk of forming dangerous blood clots, were presented this week at the American Heart Association (AHA) Scientific Ses...
|
|
ARYx Reports Third Quarter 2008 Financial Results
Nov 12, 2008
|
18.2 KB |
|
| |
FREMONT, Calif., Nov 12, 2008 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (NASDAQ:ARYX) today reported results of operations and provided an update on its products for the third quarter ended September 30, 2008. An announcement of the completion of an agreement to raise $21.6 million in a private placement is contained in an accompanying press relea...
|
|
ARYx Therapeutics Inc. Announces $21.6 Million Private Placement -- New Funding Improves Strategic Position for Product Collaborations
Nov 12, 2008
|
11.2 KB |
|
| |
FREMONT, Calif., Nov 12, 2008 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced that it has entered into a securities purchase agreement in connection with a private placement to a group of accredited investors led by new investor New Enterprise Associates (NEA) with participation from significant existing shareholders includ...
|
|
ARYx Therapeutics Schedules Third Quarter 2008 Results and Earnings Call
Nov 5, 2008
|
9.5 KB |
|
| |
FREMONT, Calif., Nov 05, 2008 (BUSINESS WIRE) -- ARYx Therapeutics Inc. (NASDAQ:ARYX), a biopharmaceutical company, announced today that a conference call to discuss third quarter 2008 results will be held on Wednesday, November 12, 2008 at 8:00 a.m. Pacific Time.
The dial-in information for the call is as follows:
Dial In: 877-604-9674
Di...
|
|
ARYx Therapeutics Inc. Completes Enrollment in EmbraceAC Study -- Phase 2/3 Clinical Trial Comparing Anticoagulant ATI-5923 Against Warfarin
Nov 3, 2008
|
14.0 KB |
|
| |
FREMONT, Calif., Nov 03, 2008 (BUSINESS WIRE) -- ARYx Therapeutics Inc. (NASDAQ:ARYX), a biopharmaceutical company, today announced it has completed enrollment in EmbraceAC, a Phase 2/3 double-blind clinical trial comparing its oral anticoagulation therapy, ATI-5923, against the leading anticoagulant agent, warfarin. The purpose of the trial is to ...
|
|
ARYx to Present at the Oppenheimer & Co. 19th Annual Health Care Conference
Oct 28, 2008
|
9.3 KB |
|
| |
FREMONT, Calif., Oct 28, 2008 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced that it will present at the Oppenheimer & Co. 19th Annual Health Care Conference in New York, NY. A live webcast of the presentation scheduled for Tuesday, November 4 at 2:40 p.m. Eastern Time may be accessed at the ARYx website http://www.aryx.co...
|
|
ARYx Therapeutics Appoints Amgen Executive to Board of Directors
Aug 29, 2008
|
10.1 KB |
|
| |
FREMONT, Calif., Aug 29, 2008 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced the appointment of David Beier to its board of directors. Mr. Beier is a veteran of the biotechnology industry and has been instrumental in the development of United States public policy impacting biotechnology companies, having served in both the...
|
|
ARYx Therapeutics, Inc. Announces Successful Results of Chronic Constipation Clinical Trial on ATI-7505
Aug 22, 2008
|
14.3 KB |
|
| |
FREMONT, Calif., Aug 22, 2008 (BUSINESS WIRE) -- ARYx Therapeutics, Inc., (NASDAQ:ARYX), a biopharmaceutical company, today announced the results of a Phase 2b clinical trial testing the safety and efficacy of its prokinetic agent, ATI-7505, in patients with chronic idiopathic constipation. The clinical trial, conducted by Procter and Gamble Pharma...
|
|
ARYx Reports Second Quarter 2008 Financial Results
Aug 13, 2008
|
18.3 KB |
|
| |
FREMONT, Calif., Aug 13, 2008 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (NASDAQ:ARYX) today reported results of operations and provided an update on its products for the second quarter ended June 30, 2008.
"During the second quarter of 2008, we made substantial progress in advancing our clinical and corporate programs, through the initiation o...
|
|
ARYx Therapeutics Schedules Second Quarter 2008 Results and Earnings Call
Aug 6, 2008
|
9.9 KB |
|
| |
FREMONT, Calif., Aug 06, 2008 (BUSINESS WIRE) -- ARYx Therapeutics Inc. (NASDAQ:ARYX), a biopharmaceutical company, announced today that a conference call to discuss second quarter 2008 results will be held on Wednesday, August 13, 2008 at 8:00 a.m. Pacific Time.
The dial-in information for the call is as follows:
Dial In: 866-31...
|
|
|
Print page 
Email page 
Shareholder Briefcase
Printed Materials
Download Library
RSS News Feeds
